SlideShare una empresa de Scribd logo
1 de 39
Descargar para leer sin conexión
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Stereotactic Body Radiotherapy (SBRT) for
the Inoperable Early Stage Lung Cancer Patient
Lucien A. Nedzi, M.D.Lucien A. Nedzi, M.D.
Department of Radiation OncologyDepartment of Radiation Oncology
Univ. of Texas Southwestern Medical CenterUniv. of Texas Southwestern Medical Center
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Early Stage Lung Cancer Risk Groups
3 broad groups:3 broad groups:
­ Average RiskAverage Risk
Generally can tolerate removal of anGenerally can tolerate removal of an
entire lobeentire lobe
­ High RiskHigh Risk
Can tolerate partial removal of a lobeCan tolerate partial removal of a lobe
­ MedicallyMedically InoperableInoperable
Cannot tolerate surgery for lung cancerCannot tolerate surgery for lung cancer
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Circa 1995: A new treatment called
“Extracranial Stereotactic
Radioablation” (later SBRT)
• GammaKnife-like treatments in the bodyGammaKnife-like treatments in the body
• Swedish pioneers Ingmar Lax and HenricSwedish pioneers Ingmar Lax and Henric
BlomgrenBlomgren
• Japanese pioneer Minoru UematsuJapanese pioneer Minoru Uematsu
• Facilitated by technology (immobilization, motionFacilitated by technology (immobilization, motion
control, 3-D dosimetry, image-guidance)control, 3-D dosimetry, image-guidance)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
What Characterizes Stereotactic
Body Radiation Therapy
(SBRT)?
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Spread out the entry radiation
damage
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Punishing Radiation Target Dose
­This dose defines tumor control (place it well)This dose defines tumor control (place it well)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Steep Radiation Gradients to Normal Tissue
­This intermediate doseThis intermediate dose
­Can kill microscopic tumor tentaclesCan kill microscopic tumor tentacles
­BUT, accounts for toxicity.BUT, accounts for toxicity.
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Very large low dose radiation volume
- SBRT (and radiosurgery) Assumption: A little dose to a lot of- SBRT (and radiosurgery) Assumption: A little dose to a lot of
normal tissue is better than a lot of dose to a little normal tissuenormal tissue is better than a lot of dose to a little normal tissue
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
SBRT Treatment Logistics
OutpatientOutpatient
No Sedation orNo Sedation or
AnesthesiaAnesthesia
(painless)(painless)
1-5 Treatments1-5 Treatments
qd or qodqd or qod
20-60 Minutes20-60 Minutes
Per TreatmentPer Treatment
Immediate ReturnImmediate Return
To ActivitiesTo Activities
Entire course ofEntire course of
Rx in 1-2 weeksRx in 1-2 weeks
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Tissue Effects After SBRT
• Dramatic tumor responses even in solid organsDramatic tumor responses even in solid organs
• Solid organ–sloughing unlikely contributing to responseSolid organ–sloughing unlikely contributing to response
• Implies SBRT preserves competence of immune systemImplies SBRT preserves competence of immune system
to carry out phagocytosisto carry out phagocytosis
Pre-treatmentPre-treatment 6 weeks6 weeks
post-treatmentpost-treatment
3 years3 years
post-treatmentpost-treatment
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Tissue Effects After SBRT
• Normal tissue collateral damage does occurNormal tissue collateral damage does occur
­ Dose and location dependantDose and location dependant
­ Adjacent tissue doesn’t function (ablated)Adjacent tissue doesn’t function (ablated)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Summary of SBRT
• Very convenient and non-invasiveVery convenient and non-invasive
• Technology intensive and dependantTechnology intensive and dependant
• In contrast to CFRT, local immune function appears mostlyIn contrast to CFRT, local immune function appears mostly
preservedpreserved
­ Dramatic tumor responsesDramatic tumor responses
­ Avoidance of necrosisAvoidance of necrosis
• Immediately surrounding normal tissue is damaged to theImmediately surrounding normal tissue is damaged to the
point of dysfunctionpoint of dysfunction
­ Decreased organ reserve (?symptomatic)Decreased organ reserve (?symptomatic)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
3-5 Year Outcome in
Early Stage Lung Cancer
Rx ModalityRx Modality % alive% alive
• Stage IStage I SurgerySurgery 60-80%60-80%
Stage I*Stage I* Conventional XRTConventional XRT 15-45%15-45%
*clinically staged and mostly medically inoperable (some*clinically staged and mostly medically inoperable (some
refused surgery)refused surgery)
Conventional RT generally 60-66 Gy delivered in 6-7 weeksConventional RT generally 60-66 Gy delivered in 6-7 weeks
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Early Investigations of SBRT
• Mostly ad hoc, retrospectiveMostly ad hoc, retrospective
• Treated typical drug discovery phase I populationTreated typical drug discovery phase I population
­ Incurable patientsIncurable patients
­ Metastatic cancerMetastatic cancer
­ Near end of lifeNear end of life
• Difficult to draw conclusionsDifficult to draw conclusions
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
SBRT in Early Stage NSCLC
• First prospective trials were in medicallyFirst prospective trials were in medically
inoperable patients with stage I NSCLCinoperable patients with stage I NSCLC
­ Those refusing surgery (confounders) not allowedThose refusing surgery (confounders) not allowed
• Intent, originally, was to improve tumor controlIntent, originally, was to improve tumor control
­ probably at the expense of increased toxicityprobably at the expense of increased toxicity
• Experience has been that tumor control isExperience has been that tumor control is
improved and treatment is surprisingly wellimproved and treatment is surprisingly well
toleratedtolerated
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
• Classic phase I designClassic phase I design
• Low starting dose 8 Gy X 3 = 24 GyLow starting dose 8 Gy X 3 = 24 Gy
• Dose escalation to very high doses 20-Dose escalation to very high doses 20-
24 Gy X 3 = 60-72 Gy24 Gy X 3 = 60-72 Gy
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Tumor Control Definitions
• Follow-up policy and control definitions:Follow-up policy and control definitions:
­ CT scan q3 monthsCT scan q3 months
­ Progressive CT consolidation within or adjacent toProgressive CT consolidation within or adjacent to
tumor prompt PETtumor prompt PET
­ If PET has uptake similar to initial staging (EORTCIf PET has uptake similar to initial staging (EORTC
criteria), then score as tumor recurrencecriteria), then score as tumor recurrence
­ Otherwise continue to follow (NED)Otherwise continue to follow (NED)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
72 yo female with T1N0M0 NSCLC s/p
SBRT 54Gy/3 fractions to 73% dose line,
dose at iso=73.97Gy, 10 beams
Example
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Treatment Plan
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Follow-up
• 3 month scan with good response3 month scan with good response
• 6 months post SBRT develops cough, fever,6 months post SBRT develops cough, fever,
SOB, and chest wall painSOB, and chest wall pain
• Original PET SUV 9-10, repeat PET SUV 3-5Original PET SUV 9-10, repeat PET SUV 3-5
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Follow-up
• Treated with incentive spirometry, prednisoneTreated with incentive spirometry, prednisone
taper, albuterol nebulizers for pneumonitistaper, albuterol nebulizers for pneumonitis
• Symptoms improve graduallySymptoms improve gradually
Pre SBRTPre SBRT 2 years post SBRT2 years post SBRT
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Dose_Levels
2400 to 3600
4200 to 5400
6000 to 7200
Local Control
0 12 24 36 48 60 72 84 96
100
90
80
70
60
50
40
30
20
10
0
Months from Therapy
LocalRecurrenceFreeSurvival(%)
P = 0.01 (log rank)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Dose Response
0
20
40
60
80
100
0 10 20 30 40 50 60 70
Total Dose in 3 Fractions
4-yearLocalControl
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
• IU 70 patient phase II studyIU 70 patient phase II study
• 20 Gy X 3 for T120 Gy X 3 for T1
22 Gy X 3 for T222 Gy X 3 for T2
• NO restriction on tumorNO restriction on tumor
locationlocation
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Zone of the Proximal Bronchial Tree
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
RTOG 0236
• Non-small cell lung cancer - biopsy provenNon-small cell lung cancer - biopsy proven
• T1, T2 (T1, T2 (≤≤ 5 cm)5 cm)
• Medical problems preclude surgeryMedical problems preclude surgery
(e.g. emphysema, heart disease, diabetes)(e.g. emphysema, heart disease, diabetes)
• No other planned therapyNo other planned therapy
Staging was non-invasive (PET/CT)Staging was non-invasive (PET/CT)
Only invasive step
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Primary Tumor Control
One patient failed within 2 cm of the primary tumor
LocalControl(%)
0
25
50
75
100
MonthsafterStartofSBRT
0 6 12 18 24 30 36
0
25
50
75
100
0 6 12 18 24 30 36
Patients
atRisk 55 54 47 46 39 34 23
Fail: 1
Total: 55
/ / / / / /// / / // / // / / / / / // / // // // //
36 month primary tumor
Control = 98% (CI: 84-100%)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Local Control
• Local recurrence is primary tumor failure and/orLocal recurrence is primary tumor failure and/or
failure within the involved lobe of the lungfailure within the involved lobe of the lung
• 1 patient had primary tumor failure1 patient had primary tumor failure
++
3 patients had failure within the involved lobe3 patients had failure within the involved lobe
• 3-year Kaplan Meier local control = 90.7%3-year Kaplan Meier local control = 90.7%
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Regional Recurrence
• 2 patients have reported a regional failure, both2 patients have reported a regional failure, both
after 2 years (2.8 and 3.0 years)after 2 years (2.8 and 3.0 years)
• Patients avoiding both local and regionalPatients avoiding both local and regional
recurrence (loco-regional control) is 87.2%recurrence (loco-regional control) is 87.2%
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Disseminated Recurrence
• Eleven patients (20%) have experiencedEleven patients (20%) have experienced
disseminated failuredisseminated failure
­ 8 of these patients had failure prior to 2 years8 of these patients had failure prior to 2 years
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Overall Survival
OverallSurvival(%)
0
25
50
75
100
MonthsafterStartofSBRT
0 6 12 18 24 30 36
0
25
50
75
100
0 6 12 18 24 30 36
Patients
atRisk 55 54 47 46 40 35 24
Dead: 26
Total: 55
MST: 48.1
(95%CI): (29.6,notreached)
/
// / / //36 month
overall survival = 56% (CI: 42-68%)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Severe Toxicity
• No grade 5 toxicities (treatment deaths)No grade 5 toxicities (treatment deaths)
• Two (4%) grade 4 protocol specifiedTwo (4%) grade 4 protocol specified
toxicity (decline in PFTs to <25%toxicity (decline in PFTs to <25%
predicted & hypocalcemia)predicted & hypocalcemia)
• Seven (13%) grade 3 protocol specifiedSeven (13%) grade 3 protocol specified
toxicitiestoxicities
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Protocol Specified Grade 3 Toxicities
• 1 patient: low oxygen in blood (O1 patient: low oxygen in blood (O22
required)required)
• 2 patient: radiation inflammation of lung2 patient: radiation inflammation of lung
(O(O22 required)required)
• 3 patients: decline in pulmonary3 patients: decline in pulmonary
function, (25-50% of predicted value)function, (25-50% of predicted value)
• 1 patient: decline in pulmonary function1 patient: decline in pulmonary function
and coughand cough
= 7= 7 patients (all pulmonary toxicity)patients (all pulmonary toxicity)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
• SBRT has become a standard of care for medicallySBRT has become a standard of care for medically
inoperable patientsinoperable patients
­ No randomized trial deemed necessaryNo randomized trial deemed necessary
­ Up to 10,000 patients per year in USUp to 10,000 patients per year in US
• Successful clinical model using hypofractionatedSuccessful clinical model using hypofractionated
radiotherapy:radiotherapy:
• Rigorously conducted, highly scrutinizedRigorously conducted, highly scrutinized
• Multicenter QAMulticenter QA
• Rapid acceptanceRapid acceptance
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Multicenter Phase II Trials Medically Inoperable
• Dutch InvestigatorsDutch Investigators
­ 206 patients with Stage I206 patients with Stage I
­ Risk adapted approach well toleratedRisk adapted approach well tolerated
­ Primary tumor recurrence 3%, regional failure 9%, 2 year OSPrimary tumor recurrence 3%, regional failure 9%, 2 year OS
64%64%
• JCOG 0403JCOG 0403
­ Peripheral T1a, N0, M0Peripheral T1a, N0, M0
­ 100 patients – still enrolling100 patients – still enrolling
• Nordic Study GroupNordic Study Group
­ peripheral T1-T2, N0, M0peripheral T1-T2, N0, M0
­ completed accrual of 57 patients 9/2005completed accrual of 57 patients 9/2005
­ Primary tumor recurrence 7%, 2 year OS 65%Primary tumor recurrence 7%, 2 year OS 65%
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Future Directions
• Refine SBRT for medically inoperable patientsRefine SBRT for medically inoperable patients
­ Refine dose constraints with dosimetry databases andRefine dose constraints with dosimetry databases and
patient outcomespatient outcomes
­ Refine dose prescription comparing variousRefine dose prescription comparing various
fractionation regimens (RTOG 0915)fractionation regimens (RTOG 0915)
­ Refine dose prescription for centrally located tumorsRefine dose prescription for centrally located tumors
via phase I trial (RTOG 0813)via phase I trial (RTOG 0813)
­ Refine therapy in combination with systemic therapiesRefine therapy in combination with systemic therapies
• Explore use of SBRT in an operable patientExplore use of SBRT in an operable patient
subset (RTOG 0618)subset (RTOG 0618)
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
ACOSOG Z4099 / RTOG 1021
PIs: Hiran C. Fernando, MD (ACOSOG); Robert Timmerman, MD (RTOG)
Patients randomized to SBRT will receive 18Gy in three fractions, for a total dose of
54Gy.
Brachytherapy is allowed with SR.
All registered patients will be followed for study endpoints, regardless of the status of
their treatment. That includes patients receiving adjuvant therapy for any reason.
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Conclusions
• SBRT for lung cancer is effective and tolerableSBRT for lung cancer is effective and tolerable
­ Prospectively studiedProspectively studied
­ Encouraging and reproducible resultsEncouraging and reproducible results
­ Admittedly imperfect therapy with both failure and harmAdmittedly imperfect therapy with both failure and harm
• SBRT is an established standard therapy forSBRT is an established standard therapy for
medically inoperable patientsmedically inoperable patients
• SBRT should be compared to less invasive/lessSBRT should be compared to less invasive/less
radical surgery in high risk operable patientsradical surgery in high risk operable patients
­ Momentum extremely strong for SBRT, but ideallyMomentum extremely strong for SBRT, but ideally
studies will be donestudies will be done
DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY
Acknowledgements
• UTSW Rad OncUTSW Rad Onc
­ Robert Timmerman, M.D.Robert Timmerman, M.D.
­ Hak Choy, M.D.Hak Choy, M.D.
­ Ramzi Abdulrahman, M.D.Ramzi Abdulrahman, M.D.
­ Lech Papiez, Ph.D.Lech Papiez, Ph.D.
­ Timothy Solberg, Ph.D.Timothy Solberg, Ph.D.
• UTSW CT SurgeryUTSW CT Surgery
­ Michael Wait, M.D.Michael Wait, M.D.
­ Michael Dimiao, M.D.Michael Dimiao, M.D.
• UTSW Med OncUTSW Med Onc
­ Joan Schiller, M.D.Joan Schiller, M.D.
­ David Gerber, M.D.David Gerber, M.D.
• RTOG HeadquartersRTOG Headquarters
­ Rebecca Paulus, Ph.D.Rebecca Paulus, Ph.D.
­ Linda Walters, M.S.Linda Walters, M.S.
• RTOG CollaboratorsRTOG Collaborators
­ Jeff Bradley, M.D.Jeff Bradley, M.D.
­ Harvey Pass, M.D.Harvey Pass, M.D.
• RPCRPC
­ Goeff Ibbott, Ph.D.Goeff Ibbott, Ph.D.
­ David Followill, Ph.D.David Followill, Ph.D.
• ATC/ITCATC/ITC
­ Jeff Michalski, M.D.Jeff Michalski, M.D.
­ Walter Bosch, Ph.D.Walter Bosch, Ph.D.
­ Bill Straube, Ph.D.Bill Straube, Ph.D.

Más contenido relacionado

La actualidad más candente

SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief OverviewSBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief OverviewTodd Scarbrough
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancerfondas vakalis
 
Novel RT techniques for treating lung cancer 1403
Novel RT techniques for treating lung cancer 1403Novel RT techniques for treating lung cancer 1403
Novel RT techniques for treating lung cancer 1403Yong Chan Ahn
 
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancerpostmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancerBharti Devnani
 
Radiosurgery for lung cancer short version
Radiosurgery for lung cancer short versionRadiosurgery for lung cancer short version
Radiosurgery for lung cancer short versionRobert J Miller MD
 
Early Lung Cancer: Radiosurgery
Early Lung Cancer: RadiosurgeryEarly Lung Cancer: Radiosurgery
Early Lung Cancer: Radiosurgeryduttaradio
 
Adjuvant radiation based on genomic risk factors emerging scenarios
Adjuvant radiation based on genomic risk factors   emerging scenariosAdjuvant radiation based on genomic risk factors   emerging scenarios
Adjuvant radiation based on genomic risk factors emerging scenariosSantam Chakraborty
 
Stereotactic body radiation therapy
Stereotactic body radiation therapyStereotactic body radiation therapy
Stereotactic body radiation therapyumesh V
 
Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...
Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...
Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...Gemelli Advanced Radiation Therapy
 
Personalised medicine in rt dr. ashutosh
Personalised medicine in rt   dr. ashutoshPersonalised medicine in rt   dr. ashutosh
Personalised medicine in rt dr. ashutoshAshutosh Mukherji
 
Sarcoma brachytherapy updates
Sarcoma brachytherapy updatesSarcoma brachytherapy updates
Sarcoma brachytherapy updatesAshutosh Mukherji
 
Srs debate dr. ashutosh mukherji
Srs debate   dr. ashutosh mukherjiSrs debate   dr. ashutosh mukherji
Srs debate dr. ashutosh mukherjiAshutosh Mukherji
 
radiotherapy of bone metastases,Vakalis
radiotherapy of bone metastases,Vakalisradiotherapy of bone metastases,Vakalis
radiotherapy of bone metastases,Vakalisfondas vakalis
 
1509 webinar oligometa lung
1509 webinar oligometa lung1509 webinar oligometa lung
1509 webinar oligometa lungYong Chan Ahn
 

La actualidad más candente (20)

What's new in Cancer Treatment: Radiation
What's new in Cancer Treatment: RadiationWhat's new in Cancer Treatment: Radiation
What's new in Cancer Treatment: Radiation
 
SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief OverviewSBRT/SABR for Early Stage Lung Cancer: A Brief Overview
SBRT/SABR for Early Stage Lung Cancer: A Brief Overview
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancer
 
Stereotactic Radiosurgery for Lung Cancer
Stereotactic Radiosurgery for Lung CancerStereotactic Radiosurgery for Lung Cancer
Stereotactic Radiosurgery for Lung Cancer
 
Lung sbrt ppt
Lung  sbrt pptLung  sbrt ppt
Lung sbrt ppt
 
Novel RT techniques for treating lung cancer 1403
Novel RT techniques for treating lung cancer 1403Novel RT techniques for treating lung cancer 1403
Novel RT techniques for treating lung cancer 1403
 
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancerpostmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
 
Radiosurgery for lung cancer short version
Radiosurgery for lung cancer short versionRadiosurgery for lung cancer short version
Radiosurgery for lung cancer short version
 
Radiotherapy sarcomas
Radiotherapy sarcomas Radiotherapy sarcomas
Radiotherapy sarcomas
 
Early Lung Cancer: Radiosurgery
Early Lung Cancer: RadiosurgeryEarly Lung Cancer: Radiosurgery
Early Lung Cancer: Radiosurgery
 
Adjuvant radiation based on genomic risk factors emerging scenarios
Adjuvant radiation based on genomic risk factors   emerging scenariosAdjuvant radiation based on genomic risk factors   emerging scenarios
Adjuvant radiation based on genomic risk factors emerging scenarios
 
Stereotactic body radiation therapy
Stereotactic body radiation therapyStereotactic body radiation therapy
Stereotactic body radiation therapy
 
Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...
Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...
Trattamenti stereo-RT e radiochirurgici come opzioni standard di trattamento:...
 
Personalised medicine in rt dr. ashutosh
Personalised medicine in rt   dr. ashutoshPersonalised medicine in rt   dr. ashutosh
Personalised medicine in rt dr. ashutosh
 
BALKAN MCO 2011 - E. Vrdoljak - Radiotherapy
BALKAN MCO 2011 - E. Vrdoljak - RadiotherapyBALKAN MCO 2011 - E. Vrdoljak - Radiotherapy
BALKAN MCO 2011 - E. Vrdoljak - Radiotherapy
 
Sarcoma brachytherapy updates
Sarcoma brachytherapy updatesSarcoma brachytherapy updates
Sarcoma brachytherapy updates
 
Srs debate dr. ashutosh mukherji
Srs debate   dr. ashutosh mukherjiSrs debate   dr. ashutosh mukherji
Srs debate dr. ashutosh mukherji
 
radiotherapy of bone metastases,Vakalis
radiotherapy of bone metastases,Vakalisradiotherapy of bone metastases,Vakalis
radiotherapy of bone metastases,Vakalis
 
1509 webinar oligometa lung
1509 webinar oligometa lung1509 webinar oligometa lung
1509 webinar oligometa lung
 
SBRT in lung cancer
SBRT in lung cancerSBRT in lung cancer
SBRT in lung cancer
 

Similar a sbrt for inoperable lung cancer

Role of radiotherapy and chemotherapy in oral cavity cancer
Role of radiotherapy and chemotherapy in oral cavity cancerRole of radiotherapy and chemotherapy in oral cavity cancer
Role of radiotherapy and chemotherapy in oral cavity cancerDr.Rashmi Yadav
 
Radiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung CancerRadiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung Cancerflasco_org
 
peronalizovana radioterapija karcinoma dojke.pptx
peronalizovana radioterapija karcinoma dojke.pptxperonalizovana radioterapija karcinoma dojke.pptx
peronalizovana radioterapija karcinoma dojke.pptxSandraRadenkovi
 
Final retroperitoneal tumors ppt
Final retroperitoneal tumors pptFinal retroperitoneal tumors ppt
Final retroperitoneal tumors ppturooj abbasi
 
Radiation therapy for early stage hodgkin’s lymphoma
Radiation therapy for early stage hodgkin’s lymphomaRadiation therapy for early stage hodgkin’s lymphoma
Radiation therapy for early stage hodgkin’s lymphomaSandip Sarkar
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RTBharti Devnani
 
Treatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptx
Treatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptxTreatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptx
Treatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptxMuthuRamanK3
 
Management of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcomaManagement of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcomaPRARABDH95
 
Externalbeam rt in ews3.12.20 - frida yseminar-finallll
Externalbeam rt in ews3.12.20    - frida yseminar-finallllExternalbeam rt in ews3.12.20    - frida yseminar-finallll
Externalbeam rt in ews3.12.20 - frida yseminar-finallllPRARABDH95
 
2 d vs 3d planning in pelvic malignancies
2 d vs 3d planning in pelvic malignancies2 d vs 3d planning in pelvic malignancies
2 d vs 3d planning in pelvic malignanciesAbhishek Soni
 
Tumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancerTumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancerRanjita Pallavi
 
Stereotactic Body Radiation Therapy
Stereotactic Body Radiation TherapyStereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapyfondas vakalis
 
Current Concept of Management Gastric Carcinoma
Current Concept of Management Gastric CarcinomaCurrent Concept of Management Gastric Carcinoma
Current Concept of Management Gastric Carcinomadrmangual1954
 

Similar a sbrt for inoperable lung cancer (20)

Brain metastasis
Brain metastasisBrain metastasis
Brain metastasis
 
Nasopharynx
Nasopharynx Nasopharynx
Nasopharynx
 
Role of radiotherapy and chemotherapy in oral cavity cancer
Role of radiotherapy and chemotherapy in oral cavity cancerRole of radiotherapy and chemotherapy in oral cavity cancer
Role of radiotherapy and chemotherapy in oral cavity cancer
 
Radiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung CancerRadiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung Cancer
 
10 may sbrt
10 may sbrt10 may sbrt
10 may sbrt
 
peronalizovana radioterapija karcinoma dojke.pptx
peronalizovana radioterapija karcinoma dojke.pptxperonalizovana radioterapija karcinoma dojke.pptx
peronalizovana radioterapija karcinoma dojke.pptx
 
Final retroperitoneal tumors ppt
Final retroperitoneal tumors pptFinal retroperitoneal tumors ppt
Final retroperitoneal tumors ppt
 
Radiation therapy for early stage hodgkin’s lymphoma
Radiation therapy for early stage hodgkin’s lymphomaRadiation therapy for early stage hodgkin’s lymphoma
Radiation therapy for early stage hodgkin’s lymphoma
 
Ca oral cavity management
Ca oral cavity managementCa oral cavity management
Ca oral cavity management
 
Radiation therapy in gynecologic cancer 17-03-15
Radiation therapy in gynecologic cancer 17-03-15Radiation therapy in gynecologic cancer 17-03-15
Radiation therapy in gynecologic cancer 17-03-15
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
 
Treatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptx
Treatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptxTreatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptx
Treatment of Advanced stage of Carcinoma Cervix & Ca cervix in Pregnancy.pptx
 
Retroperitoneal sarcoma
Retroperitoneal sarcomaRetroperitoneal sarcoma
Retroperitoneal sarcoma
 
Management of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcomaManagement of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcoma
 
Externalbeam rt in ews3.12.20 - frida yseminar-finallll
Externalbeam rt in ews3.12.20    - frida yseminar-finallllExternalbeam rt in ews3.12.20    - frida yseminar-finallll
Externalbeam rt in ews3.12.20 - frida yseminar-finallll
 
2 d vs 3d planning in pelvic malignancies
2 d vs 3d planning in pelvic malignancies2 d vs 3d planning in pelvic malignancies
2 d vs 3d planning in pelvic malignancies
 
Xxxxxxcddf
XxxxxxcddfXxxxxxcddf
Xxxxxxcddf
 
Tumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancerTumor board locally advanced rectal cancer
Tumor board locally advanced rectal cancer
 
Stereotactic Body Radiation Therapy
Stereotactic Body Radiation TherapyStereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy
 
Current Concept of Management Gastric Carcinoma
Current Concept of Management Gastric CarcinomaCurrent Concept of Management Gastric Carcinoma
Current Concept of Management Gastric Carcinoma
 

Más de fondas vakalis

Esophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-VakalisEsophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-Vakalisfondas vakalis
 
radiotherapy-pancreatic cancer
radiotherapy-pancreatic cancerradiotherapy-pancreatic cancer
radiotherapy-pancreatic cancerfondas vakalis
 
Spinal cord compression bhf aos study day mar 2014 final
Spinal cord compression bhf  aos study day mar 2014 finalSpinal cord compression bhf  aos study day mar 2014 final
Spinal cord compression bhf aos study day mar 2014 finalfondas vakalis
 
Vakalis breast radiotherapy
Vakalis breast radiotherapyVakalis breast radiotherapy
Vakalis breast radiotherapyfondas vakalis
 
Vakalis - RT for prostate cancer
Vakalis  - RT for prostate cancerVakalis  - RT for prostate cancer
Vakalis - RT for prostate cancerfondas vakalis
 
Her2 positive metastatic breast ca
Her2 positive metastatic breast caHer2 positive metastatic breast ca
Her2 positive metastatic breast cafondas vakalis
 
Advanced breast cancer
Advanced breast cancerAdvanced breast cancer
Advanced breast cancerfondas vakalis
 
Second line therapy for nsclc
Second line therapy for nsclcSecond line therapy for nsclc
Second line therapy for nsclcfondas vakalis
 
HER2 negative metastatic breast ca
HER2 negative metastatic breast caHER2 negative metastatic breast ca
HER2 negative metastatic breast cafondas vakalis
 
Radiobiology behind dose fractionation
Radiobiology behind dose fractionationRadiobiology behind dose fractionation
Radiobiology behind dose fractionationfondas vakalis
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionationfondas vakalis
 
RECTAL CA - VAKALIS . X
RECTAL CA - VAKALIS . XRECTAL CA - VAKALIS . X
RECTAL CA - VAKALIS . Xfondas vakalis
 
Vakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapyVakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapyfondas vakalis
 
testicular cancer and radiotherapy
testicular cancer and radiotherapytesticular cancer and radiotherapy
testicular cancer and radiotherapyfondas vakalis
 

Más de fondas vakalis (20)

Esophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-VakalisEsophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-Vakalis
 
radiotherapy-pancreatic cancer
radiotherapy-pancreatic cancerradiotherapy-pancreatic cancer
radiotherapy-pancreatic cancer
 
Spinal cord compression bhf aos study day mar 2014 final
Spinal cord compression bhf  aos study day mar 2014 finalSpinal cord compression bhf  aos study day mar 2014 final
Spinal cord compression bhf aos study day mar 2014 final
 
Vakalis breast radiotherapy
Vakalis breast radiotherapyVakalis breast radiotherapy
Vakalis breast radiotherapy
 
Vakalis - RT for prostate cancer
Vakalis  - RT for prostate cancerVakalis  - RT for prostate cancer
Vakalis - RT for prostate cancer
 
Her2 positive metastatic breast ca
Her2 positive metastatic breast caHer2 positive metastatic breast ca
Her2 positive metastatic breast ca
 
nonsquamous NSCLC
nonsquamous NSCLCnonsquamous NSCLC
nonsquamous NSCLC
 
Advanced breast cancer
Advanced breast cancerAdvanced breast cancer
Advanced breast cancer
 
Second line therapy for nsclc
Second line therapy for nsclcSecond line therapy for nsclc
Second line therapy for nsclc
 
Vegf in colorectal ca
Vegf in colorectal caVegf in colorectal ca
Vegf in colorectal ca
 
HER2 negative metastatic breast ca
HER2 negative metastatic breast caHER2 negative metastatic breast ca
HER2 negative metastatic breast ca
 
817731 slides
817731 slides817731 slides
817731 slides
 
Radiobiology behind dose fractionation
Radiobiology behind dose fractionationRadiobiology behind dose fractionation
Radiobiology behind dose fractionation
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation
 
RECTAL CA - VAKALIS . X
RECTAL CA - VAKALIS . XRECTAL CA - VAKALIS . X
RECTAL CA - VAKALIS . X
 
Vakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapyVakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapy
 
Vakalis.X H&N CANCER
Vakalis.X  H&N CANCERVakalis.X  H&N CANCER
Vakalis.X H&N CANCER
 
Vakalis pancreas
Vakalis pancreasVakalis pancreas
Vakalis pancreas
 
Vakalis prostate
Vakalis prostateVakalis prostate
Vakalis prostate
 
testicular cancer and radiotherapy
testicular cancer and radiotherapytesticular cancer and radiotherapy
testicular cancer and radiotherapy
 

Último

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 

Último (20)

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 

sbrt for inoperable lung cancer

  • 1. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Stereotactic Body Radiotherapy (SBRT) for the Inoperable Early Stage Lung Cancer Patient Lucien A. Nedzi, M.D.Lucien A. Nedzi, M.D. Department of Radiation OncologyDepartment of Radiation Oncology Univ. of Texas Southwestern Medical CenterUniv. of Texas Southwestern Medical Center
  • 2. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Early Stage Lung Cancer Risk Groups 3 broad groups:3 broad groups: ­ Average RiskAverage Risk Generally can tolerate removal of anGenerally can tolerate removal of an entire lobeentire lobe ­ High RiskHigh Risk Can tolerate partial removal of a lobeCan tolerate partial removal of a lobe ­ MedicallyMedically InoperableInoperable Cannot tolerate surgery for lung cancerCannot tolerate surgery for lung cancer
  • 3. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Circa 1995: A new treatment called “Extracranial Stereotactic Radioablation” (later SBRT) • GammaKnife-like treatments in the bodyGammaKnife-like treatments in the body • Swedish pioneers Ingmar Lax and HenricSwedish pioneers Ingmar Lax and Henric BlomgrenBlomgren • Japanese pioneer Minoru UematsuJapanese pioneer Minoru Uematsu • Facilitated by technology (immobilization, motionFacilitated by technology (immobilization, motion control, 3-D dosimetry, image-guidance)control, 3-D dosimetry, image-guidance)
  • 4. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY What Characterizes Stereotactic Body Radiation Therapy (SBRT)?
  • 5. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Spread out the entry radiation damage
  • 6. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Punishing Radiation Target Dose ­This dose defines tumor control (place it well)This dose defines tumor control (place it well)
  • 7. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Steep Radiation Gradients to Normal Tissue ­This intermediate doseThis intermediate dose ­Can kill microscopic tumor tentaclesCan kill microscopic tumor tentacles ­BUT, accounts for toxicity.BUT, accounts for toxicity.
  • 8. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Very large low dose radiation volume - SBRT (and radiosurgery) Assumption: A little dose to a lot of- SBRT (and radiosurgery) Assumption: A little dose to a lot of normal tissue is better than a lot of dose to a little normal tissuenormal tissue is better than a lot of dose to a little normal tissue
  • 9. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY SBRT Treatment Logistics OutpatientOutpatient No Sedation orNo Sedation or AnesthesiaAnesthesia (painless)(painless) 1-5 Treatments1-5 Treatments qd or qodqd or qod 20-60 Minutes20-60 Minutes Per TreatmentPer Treatment Immediate ReturnImmediate Return To ActivitiesTo Activities Entire course ofEntire course of Rx in 1-2 weeksRx in 1-2 weeks
  • 10. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Tissue Effects After SBRT • Dramatic tumor responses even in solid organsDramatic tumor responses even in solid organs • Solid organ–sloughing unlikely contributing to responseSolid organ–sloughing unlikely contributing to response • Implies SBRT preserves competence of immune systemImplies SBRT preserves competence of immune system to carry out phagocytosisto carry out phagocytosis Pre-treatmentPre-treatment 6 weeks6 weeks post-treatmentpost-treatment 3 years3 years post-treatmentpost-treatment
  • 11. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Tissue Effects After SBRT • Normal tissue collateral damage does occurNormal tissue collateral damage does occur ­ Dose and location dependantDose and location dependant ­ Adjacent tissue doesn’t function (ablated)Adjacent tissue doesn’t function (ablated)
  • 12. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Summary of SBRT • Very convenient and non-invasiveVery convenient and non-invasive • Technology intensive and dependantTechnology intensive and dependant • In contrast to CFRT, local immune function appears mostlyIn contrast to CFRT, local immune function appears mostly preservedpreserved ­ Dramatic tumor responsesDramatic tumor responses ­ Avoidance of necrosisAvoidance of necrosis • Immediately surrounding normal tissue is damaged to theImmediately surrounding normal tissue is damaged to the point of dysfunctionpoint of dysfunction ­ Decreased organ reserve (?symptomatic)Decreased organ reserve (?symptomatic)
  • 13. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY 3-5 Year Outcome in Early Stage Lung Cancer Rx ModalityRx Modality % alive% alive • Stage IStage I SurgerySurgery 60-80%60-80% Stage I*Stage I* Conventional XRTConventional XRT 15-45%15-45% *clinically staged and mostly medically inoperable (some*clinically staged and mostly medically inoperable (some refused surgery)refused surgery) Conventional RT generally 60-66 Gy delivered in 6-7 weeksConventional RT generally 60-66 Gy delivered in 6-7 weeks
  • 14. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Early Investigations of SBRT • Mostly ad hoc, retrospectiveMostly ad hoc, retrospective • Treated typical drug discovery phase I populationTreated typical drug discovery phase I population ­ Incurable patientsIncurable patients ­ Metastatic cancerMetastatic cancer ­ Near end of lifeNear end of life • Difficult to draw conclusionsDifficult to draw conclusions
  • 15. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY SBRT in Early Stage NSCLC • First prospective trials were in medicallyFirst prospective trials were in medically inoperable patients with stage I NSCLCinoperable patients with stage I NSCLC ­ Those refusing surgery (confounders) not allowedThose refusing surgery (confounders) not allowed • Intent, originally, was to improve tumor controlIntent, originally, was to improve tumor control ­ probably at the expense of increased toxicityprobably at the expense of increased toxicity • Experience has been that tumor control isExperience has been that tumor control is improved and treatment is surprisingly wellimproved and treatment is surprisingly well toleratedtolerated
  • 16. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY • Classic phase I designClassic phase I design • Low starting dose 8 Gy X 3 = 24 GyLow starting dose 8 Gy X 3 = 24 Gy • Dose escalation to very high doses 20-Dose escalation to very high doses 20- 24 Gy X 3 = 60-72 Gy24 Gy X 3 = 60-72 Gy
  • 17. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Tumor Control Definitions • Follow-up policy and control definitions:Follow-up policy and control definitions: ­ CT scan q3 monthsCT scan q3 months ­ Progressive CT consolidation within or adjacent toProgressive CT consolidation within or adjacent to tumor prompt PETtumor prompt PET ­ If PET has uptake similar to initial staging (EORTCIf PET has uptake similar to initial staging (EORTC criteria), then score as tumor recurrencecriteria), then score as tumor recurrence ­ Otherwise continue to follow (NED)Otherwise continue to follow (NED)
  • 18. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY 72 yo female with T1N0M0 NSCLC s/p SBRT 54Gy/3 fractions to 73% dose line, dose at iso=73.97Gy, 10 beams Example
  • 19. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Treatment Plan
  • 20. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Follow-up • 3 month scan with good response3 month scan with good response • 6 months post SBRT develops cough, fever,6 months post SBRT develops cough, fever, SOB, and chest wall painSOB, and chest wall pain • Original PET SUV 9-10, repeat PET SUV 3-5Original PET SUV 9-10, repeat PET SUV 3-5
  • 21. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Follow-up • Treated with incentive spirometry, prednisoneTreated with incentive spirometry, prednisone taper, albuterol nebulizers for pneumonitistaper, albuterol nebulizers for pneumonitis • Symptoms improve graduallySymptoms improve gradually Pre SBRTPre SBRT 2 years post SBRT2 years post SBRT
  • 22. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Dose_Levels 2400 to 3600 4200 to 5400 6000 to 7200 Local Control 0 12 24 36 48 60 72 84 96 100 90 80 70 60 50 40 30 20 10 0 Months from Therapy LocalRecurrenceFreeSurvival(%) P = 0.01 (log rank)
  • 23. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Dose Response 0 20 40 60 80 100 0 10 20 30 40 50 60 70 Total Dose in 3 Fractions 4-yearLocalControl
  • 24. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY • IU 70 patient phase II studyIU 70 patient phase II study • 20 Gy X 3 for T120 Gy X 3 for T1 22 Gy X 3 for T222 Gy X 3 for T2 • NO restriction on tumorNO restriction on tumor locationlocation
  • 25. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Zone of the Proximal Bronchial Tree
  • 26. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY RTOG 0236 • Non-small cell lung cancer - biopsy provenNon-small cell lung cancer - biopsy proven • T1, T2 (T1, T2 (≤≤ 5 cm)5 cm) • Medical problems preclude surgeryMedical problems preclude surgery (e.g. emphysema, heart disease, diabetes)(e.g. emphysema, heart disease, diabetes) • No other planned therapyNo other planned therapy Staging was non-invasive (PET/CT)Staging was non-invasive (PET/CT) Only invasive step
  • 27. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Primary Tumor Control One patient failed within 2 cm of the primary tumor LocalControl(%) 0 25 50 75 100 MonthsafterStartofSBRT 0 6 12 18 24 30 36 0 25 50 75 100 0 6 12 18 24 30 36 Patients atRisk 55 54 47 46 39 34 23 Fail: 1 Total: 55 / / / / / /// / / // / // / / / / / // / // // // // 36 month primary tumor Control = 98% (CI: 84-100%)
  • 28. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Local Control • Local recurrence is primary tumor failure and/orLocal recurrence is primary tumor failure and/or failure within the involved lobe of the lungfailure within the involved lobe of the lung • 1 patient had primary tumor failure1 patient had primary tumor failure ++ 3 patients had failure within the involved lobe3 patients had failure within the involved lobe • 3-year Kaplan Meier local control = 90.7%3-year Kaplan Meier local control = 90.7%
  • 29. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Regional Recurrence • 2 patients have reported a regional failure, both2 patients have reported a regional failure, both after 2 years (2.8 and 3.0 years)after 2 years (2.8 and 3.0 years) • Patients avoiding both local and regionalPatients avoiding both local and regional recurrence (loco-regional control) is 87.2%recurrence (loco-regional control) is 87.2%
  • 30. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Disseminated Recurrence • Eleven patients (20%) have experiencedEleven patients (20%) have experienced disseminated failuredisseminated failure ­ 8 of these patients had failure prior to 2 years8 of these patients had failure prior to 2 years
  • 31. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Overall Survival OverallSurvival(%) 0 25 50 75 100 MonthsafterStartofSBRT 0 6 12 18 24 30 36 0 25 50 75 100 0 6 12 18 24 30 36 Patients atRisk 55 54 47 46 40 35 24 Dead: 26 Total: 55 MST: 48.1 (95%CI): (29.6,notreached) / // / / //36 month overall survival = 56% (CI: 42-68%)
  • 32. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Severe Toxicity • No grade 5 toxicities (treatment deaths)No grade 5 toxicities (treatment deaths) • Two (4%) grade 4 protocol specifiedTwo (4%) grade 4 protocol specified toxicity (decline in PFTs to <25%toxicity (decline in PFTs to <25% predicted & hypocalcemia)predicted & hypocalcemia) • Seven (13%) grade 3 protocol specifiedSeven (13%) grade 3 protocol specified toxicitiestoxicities
  • 33. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Protocol Specified Grade 3 Toxicities • 1 patient: low oxygen in blood (O1 patient: low oxygen in blood (O22 required)required) • 2 patient: radiation inflammation of lung2 patient: radiation inflammation of lung (O(O22 required)required) • 3 patients: decline in pulmonary3 patients: decline in pulmonary function, (25-50% of predicted value)function, (25-50% of predicted value) • 1 patient: decline in pulmonary function1 patient: decline in pulmonary function and coughand cough = 7= 7 patients (all pulmonary toxicity)patients (all pulmonary toxicity)
  • 34. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY • SBRT has become a standard of care for medicallySBRT has become a standard of care for medically inoperable patientsinoperable patients ­ No randomized trial deemed necessaryNo randomized trial deemed necessary ­ Up to 10,000 patients per year in USUp to 10,000 patients per year in US • Successful clinical model using hypofractionatedSuccessful clinical model using hypofractionated radiotherapy:radiotherapy: • Rigorously conducted, highly scrutinizedRigorously conducted, highly scrutinized • Multicenter QAMulticenter QA • Rapid acceptanceRapid acceptance
  • 35. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Multicenter Phase II Trials Medically Inoperable • Dutch InvestigatorsDutch Investigators ­ 206 patients with Stage I206 patients with Stage I ­ Risk adapted approach well toleratedRisk adapted approach well tolerated ­ Primary tumor recurrence 3%, regional failure 9%, 2 year OSPrimary tumor recurrence 3%, regional failure 9%, 2 year OS 64%64% • JCOG 0403JCOG 0403 ­ Peripheral T1a, N0, M0Peripheral T1a, N0, M0 ­ 100 patients – still enrolling100 patients – still enrolling • Nordic Study GroupNordic Study Group ­ peripheral T1-T2, N0, M0peripheral T1-T2, N0, M0 ­ completed accrual of 57 patients 9/2005completed accrual of 57 patients 9/2005 ­ Primary tumor recurrence 7%, 2 year OS 65%Primary tumor recurrence 7%, 2 year OS 65%
  • 36. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Future Directions • Refine SBRT for medically inoperable patientsRefine SBRT for medically inoperable patients ­ Refine dose constraints with dosimetry databases andRefine dose constraints with dosimetry databases and patient outcomespatient outcomes ­ Refine dose prescription comparing variousRefine dose prescription comparing various fractionation regimens (RTOG 0915)fractionation regimens (RTOG 0915) ­ Refine dose prescription for centrally located tumorsRefine dose prescription for centrally located tumors via phase I trial (RTOG 0813)via phase I trial (RTOG 0813) ­ Refine therapy in combination with systemic therapiesRefine therapy in combination with systemic therapies • Explore use of SBRT in an operable patientExplore use of SBRT in an operable patient subset (RTOG 0618)subset (RTOG 0618)
  • 37. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY ACOSOG Z4099 / RTOG 1021 PIs: Hiran C. Fernando, MD (ACOSOG); Robert Timmerman, MD (RTOG) Patients randomized to SBRT will receive 18Gy in three fractions, for a total dose of 54Gy. Brachytherapy is allowed with SR. All registered patients will be followed for study endpoints, regardless of the status of their treatment. That includes patients receiving adjuvant therapy for any reason.
  • 38. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Conclusions • SBRT for lung cancer is effective and tolerableSBRT for lung cancer is effective and tolerable ­ Prospectively studiedProspectively studied ­ Encouraging and reproducible resultsEncouraging and reproducible results ­ Admittedly imperfect therapy with both failure and harmAdmittedly imperfect therapy with both failure and harm • SBRT is an established standard therapy forSBRT is an established standard therapy for medically inoperable patientsmedically inoperable patients • SBRT should be compared to less invasive/lessSBRT should be compared to less invasive/less radical surgery in high risk operable patientsradical surgery in high risk operable patients ­ Momentum extremely strong for SBRT, but ideallyMomentum extremely strong for SBRT, but ideally studies will be donestudies will be done
  • 39. DEPT OF RADIATION ONCOLOGYDEPT OF RADIATION ONCOLOGY Acknowledgements • UTSW Rad OncUTSW Rad Onc ­ Robert Timmerman, M.D.Robert Timmerman, M.D. ­ Hak Choy, M.D.Hak Choy, M.D. ­ Ramzi Abdulrahman, M.D.Ramzi Abdulrahman, M.D. ­ Lech Papiez, Ph.D.Lech Papiez, Ph.D. ­ Timothy Solberg, Ph.D.Timothy Solberg, Ph.D. • UTSW CT SurgeryUTSW CT Surgery ­ Michael Wait, M.D.Michael Wait, M.D. ­ Michael Dimiao, M.D.Michael Dimiao, M.D. • UTSW Med OncUTSW Med Onc ­ Joan Schiller, M.D.Joan Schiller, M.D. ­ David Gerber, M.D.David Gerber, M.D. • RTOG HeadquartersRTOG Headquarters ­ Rebecca Paulus, Ph.D.Rebecca Paulus, Ph.D. ­ Linda Walters, M.S.Linda Walters, M.S. • RTOG CollaboratorsRTOG Collaborators ­ Jeff Bradley, M.D.Jeff Bradley, M.D. ­ Harvey Pass, M.D.Harvey Pass, M.D. • RPCRPC ­ Goeff Ibbott, Ph.D.Goeff Ibbott, Ph.D. ­ David Followill, Ph.D.David Followill, Ph.D. • ATC/ITCATC/ITC ­ Jeff Michalski, M.D.Jeff Michalski, M.D. ­ Walter Bosch, Ph.D.Walter Bosch, Ph.D. ­ Bill Straube, Ph.D.Bill Straube, Ph.D.